Paper Details

  1. Home
  2. Paper Details

Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial.

Author: , AlmondJ, BassiC, BegerH, BüchlerM W, DervenisC, DunnJ A, FalconiM, Fernandez-CruzL, FriessH, KerrD J, LacaineF, LinkK, NeoptolemosJ P, PapA, PederzoliP, SpoonerD, StockenD D

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Adjuvant chemotherapy revealed a potential benefit for survival in pancreatic cancer, justifying further randomised controlled trials.
Paper Details　
Original Abstract of the Article :
BACKGROUND: The role of adjuvant treatment in pancreatic cancer remains uncertain. The European Study Group for Pancreatic Cancer (ESPAC) assessed the roles of chemoradiotherapy and chemotherapy in a randomised study. METHODS: After resection, patients were randomly assigned to adjuvant chemoradiot...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/s0140-6736(01)06651-x

データ提供：米国国立医学図書館（NLM）

Adjuvant Therapy for Pancreatic Cancer: A Quest for Improved Outcomes

Pancreatic cancer is a highly aggressive and often fatal disease. This research investigates the effectiveness of adjuvant chemoradiotherapy and chemotherapy in improving survival rates after surgery for pancreatic cancer.

Adjuvant Therapy: No Benefit for Chemoradiotherapy, But Potential Benefit for Chemotherapy

The ESPAC study, a large randomized controlled trial, found no survival benefit for adjuvant chemoradiotherapy in patients with resectable pancreatic cancer. However, the study revealed potential evidence of a survival benefit for adjuvant chemotherapy, a finding that requires further investigation. These results highlight the complex nature of pancreatic cancer and the need for carefully tailored treatment strategies.

Fighting Pancreatic Cancer: A Collaborative Effort

This research underscores the importance of ongoing research into more effective therapies for pancreatic cancer. The study's findings provide valuable insights into the potential benefits of adjuvant chemotherapy and encourage further investigation into the role of different treatment modalities in improving patient outcomes.

Dr. Camel's Conclusion

This study provides important insights into the effectiveness of adjuvant therapy for pancreatic cancer, highlighting the need for a multidisciplinary approach to this complex disease. The research underscores the importance of ongoing research and clinical trials to improve patient outcomes and combat this challenging disease.

Date :
  1. Date Completed 2002-03-05
  2. Date Revised 2022-04-09
Further Info :

Pubmed ID

11716884

DOI: Digital Object Identifier

10.1016/s0140-6736(01)06651-x

Related Literature

Article Analysis
・Effective treatment of pancreatic cancer
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.